Neuroinfections and antimicrobials: do we need new molecules or new strategies?

Neuro Endocrinol Lett. 2007 Jun:28 Suppl 2:38-9.

Abstract

Within last 15 years, analyzing patterns of etiology and resistance in organisms causing neuroinfections, emergence of resistance has been observed in Slovakia in S. haemolyticus to teicoplanin (11%), Ps. aeruginosa and A. baumannii to meropenem (20%) and Candida spp. (non-albicans Candida spp.) to fluconazol (20%). There are no new antibiotics against carbapenem resistant Ps. aeruginosa and Acinetobacter baumannii.

MeSH terms

  • Anti-Infective Agents / therapeutic use*
  • Brain Diseases / drug therapy
  • Brain Diseases / microbiology
  • Candidiasis / drug therapy
  • Cross Infection / drug therapy*
  • Cross Infection / microbiology
  • Drug Resistance, Microbial*
  • Fluconazole / therapeutic use
  • Humans
  • Meningitis / drug therapy*
  • Meningitis / microbiology
  • Meropenem
  • Pseudomonas Infections / drug therapy
  • Staphylococcal Infections / drug therapy
  • Teicoplanin / therapeutic use
  • Thienamycins / therapeutic use

Substances

  • Anti-Infective Agents
  • Thienamycins
  • Teicoplanin
  • Fluconazole
  • Meropenem